Tear Sheet

Tear Sheet

Company Profile

Vistagen Therapeutics (Nasdaq: VTGN) is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of Vistagen's CNS drug candidates, PH94B, PH10, and AV-101, has a differentiated mechanism of action, a favorable safety profile in all clinical studies to date, and therapeutic potential in multiple CNS markets.

Management Team
Chief Executive Officer and Director
Chief Financial Officer
Chief Corporate Development Officer and General Counsel

Vistagen Therapeutics, Inc.

343 Allerton Avenue
South San Francisco, CA 94080

Investor Relations Contact

Vistagen Therapeutics

Mark Flather
Vice President, Investor Relations
+1(650) 577-3617
mflather@vistagen.com